Patent: 9,067,992
✉ Email this page to a colleague
Summary for Patent: 9,067,992
Title: | Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis |
Abstract: | The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis. |
Inventor(s): | Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL) |
Assignee: | AbbVie Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 14/563,056 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,067,992 |
Patent Claims: | see list of patent claims |
Details for Patent 9,067,992
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | December 31, 2002 | 9,067,992 | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | February 21, 2008 | 9,067,992 | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | April 24, 2013 | 9,067,992 | 2021-03-07 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | September 23, 2014 | 9,067,992 | 2021-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,067,992
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 201006269 | ⤷ Subscribe |
South Africa | 200810349 | ⤷ Subscribe |
South Africa | 200608097 | ⤷ Subscribe |
South Africa | 200502983 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |